Naimish Patel - May 28, 2025 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Medical Officer
Signature
Elizabeth Ryland Waldinger, attorney-in-fact
Stock symbol
CRSP
Transactions as of
May 28, 2025
Transactions value $
-$141,316
Form type
4
Date filed
5/30/2025, 05:00 PM
Previous filing
Mar 18, 2025
Next filing
Jun 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Patel Naimish Chief Medical Officer C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON Elizabeth Ryland Waldinger, attorney-in-fact 2025-05-30 0002021679

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise +10K 10K May 28, 2025 Direct F1
transaction CRSP Common Shares Sale -$141K -3.93K -39.32% $35.94 6.07K May 29, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Options Exercise -10K -25% 30K May 28, 2025 Common Shares 10K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2 Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3 This restricted stock unit award was granted on May 28, 2024 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on May 28, 2025, (ii) one quarter of the shares vesting on May 28, 2026, (iii) one quarter of the shares vesting on May 28, 2027, and (iv) one quarter of the shares vesting on May 28, 2028.